Current PartneringCurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers. CurrentPartnering publish a series of reports, providing access to critical decision making and best practice intelligence from leaders in business development and licensing.
Best practice – reports providing insight into best practice and trends in partnering CurrentPartnering was established in 2007 by Wildwood Ventures Ltd to offer an objective and informal business tool for business development executives, providing an opportunity for the dissemination of the latest trends in partnering activity within the biopharma sector.
|
List of reports from Current Partnering
|
Partnering Agreements with Novo Nordisk
1/1/2010 | published by: Current Partnering
... understand Novo Nordisk and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of ...
|
more...
|
$495.00
|
|
Partnering Agreements with Otsuka
1/1/2010 | published by: Current Partnering
... Otsuka and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements with Pfizer
1/1/2010 | published by: Current Partnering
... Pfizer and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements with Ratiopharm
1/1/2010 | published by: Current Partnering
... Ratiopharm and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements with Sanofi-Aventis
1/1/2010 | published by: Current Partnering
... Sanofi-Aventis and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements with Servier
1/1/2010 | published by: Current Partnering
... Servier and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements with Shire
1/1/2010 | published by: Current Partnering
... Shire and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements with UCB
1/1/2010 | published by: Current Partnering
... UCB and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next ...
|
more...
|
$495.00
|
|
Partnering Agreements in Diagnostics
9/1/2009 | published by: Current Partnering
... and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals ...
|
more...
|
$2,395.00
|
|
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
6/1/2009 | published by: Current Partnering
... and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery, preclinical or clinical whereby the licensee obtains a right or an option right to license the licensors oncology ...
|
more...
|
$2,395.00
|
|
Practical Guide to Finding Partners in Biopharma
4/1/2009 | published by: Current Partnering
... managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact ...
|
more...
|
$995.00
|
|
Option & Evaluation Agreements in Pharma and Biotech
3/1/2009 | published by: Current Partnering
... of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and comprehensive, the report provides details of option and evaluation agreements from 2003 to end 2008. The report provides a ...
|
more...
|
$1,995.00
|
|
Royalty Financing Agreements in Pharma, Biotech and Diagnostics
1/1/2009 | published by: Current Partnering
... and analysis of how and why companies enter royalty financing partnering deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can ...
|
more...
|
$995.00
|
|
Product & Asset Purchase Agreements in Pharma, Biotech and Diagnostics
11/1/2008 | published by: Current Partnering
... where partners have entered an agreement to dispose of or acquire said assets. The report focuses on four primary types of asset available for purchase: Business assets - the most common asset exchanging hands. Business ...
|
more...
|
$2,395.00
|
|
Partnering with Bigpharma: The Definitive Guide to Partnering Interests, Contacts & Agreements
7/1/2008 | published by: Current Partnering
... that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, ...
|
more...
|
$2,995.00
|
|
Clinical Stage Partnering Agreements in Biopharma
6/1/2008 | published by: Current Partnering
... of how and why companies enter clinical stage partnering deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to ...
|
more...
|
$2,595.00
|
|
Distribution Agreements in Biopharma
4/1/2008 | published by: Current Partnering
... and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby ...
|
more...
|
$2,395.00
|
|
Manufacturing and Supply Agreements in Biopharma
4/1/2008 | published by: Current Partnering
... analysis of how and why companies enter manufacturing and supply deals. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect ...
|
more...
|
$2,395.00
|
|
Bigpharma Partnering Agreements
3/1/2008 | published by: Current Partnering
... into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail ...
|
more...
|
$2,395.00
|
|
Merger and Acquisition Agreements in Biopharma
2/1/2008 | published by: Current Partnering
... equity transaction. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many ...
|
more...
|
$2,395.00
|
|
Co-promotion and Co-marketing Agreements in Biopharma
1/1/2008 | published by: Current Partnering
... and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research ...
|
more...
|
$2,395.00
|

